Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin launches Eslicarbazepine Acetate tablets in US
Details : Aptiom-Generic (eslicarbazepine acetate) is a sodium channel alpha subunit blocker, which is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Product Name : Aptiom-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2025
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Termination
Details : BIAL takes the lead for the marketing and distribution of Zebinix® (eslicarbazepine acetate) in Europe. Eslicarbazepine acetate is a once-daily anti-epileptic used to treat epilepsy patients with focal seizures (partial-onset seizures).
Product Name : Zebinix
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 17, 2021
Lead Product(s) : Eslicarbazepine Acetate
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Termination
Reset All
